Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as […]
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact Herceptin biosimilars are coming for Roche in the U.S., and Monday, a pair of them […]
News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial delay Here’s Monday’s shot of biopharma news of note. Source: FierceMedicalDevices News News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial […]
AbbVie scores surprisingly good Q2 results but pipeline worries persist July has been a tough month for AbbVie, marked by a stinging patent loss on its megablockbuster Humira and a […]
Soon-Shiong’s NantCell in 6M deal for underperforming CytRx cancer drug NantCell has paid $13 million up front to license CytRx’s orphan cancer drug aldoxorubicin. Source: FierceMedicalDevices News Soon-Shiong’s NantCell in […]
Still reeling from cyberattack, Merck warns some drug supplies may be delayed Merck & Co., one of the victims of the Petya cyberattack last month, has yet to fully restore […]
AnaptysBio’s chief scientific officer Moyle heads for the exit The chief scientific officer of antibody specialist AnaptysBio, Matthew Moyle, has tendered his resignation just over a year after joining the […]
Servier licenses Galapagos’ phase 1 osteoarthritis drug Servier has licensed an osteoarthritis drug from Galapagos. The French drugmaker opted in to the program and handed over another slice of the […]
Broad scientists show how 1 bad gene takes a toll on 5 vascular diseases Migraines, coronary artery disease, high blood pressure—they may seem like different diseases but they all share […]
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to .5B Cancer drug Lynparza has been a bright spot for AstraZeneca amid generic competition for its blockbuster Crestor […]